NASDAQ:ASND
Ascendis Pharma A/S Stock News
$130.41
+0.97 (+0.749%)
At Close: May 24, 2024
– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks – –...
Ascendis Pharma announces top-line data from fixed dose portion of PaTH Forward ASND
09:49am, Sunday, 19'th Apr 2020
Ascendis Pharma announces top-line data from fixed dose portion of PaTH Forward ASND
Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT
01:40am, Friday, 17'th Apr 2020
Q4 2019 Ascendis Pharma A/S Earnings Call
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
12:09pm, Thursday, 16'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 15.) * Bio-Rad Laboratories, Inc. Class B Common Stock
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States
08:58pm, Wednesday, 15'th Apr 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the United States (U.S.) Food and Drug A
Ascendis Pharma receives FDA orphan drug designation for TransCon hGH ASND
09:59am, Wednesday, 15'th Apr 2020
Ascendis Pharma receives FDA orphan drug designation for TransCon hGH ASND
We’re Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely
10:22am, Tuesday, 14'th Apr 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Ascendis Pharma A/S (NASDAQ:ASND) Downgraded by BidaskClub
10:20am, Tuesday, 14'th Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports. Other research
Goldman Sachs Group Inc. Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
08:35am, Monday, 13'th Apr 2020
Goldman Sachs Group Inc. lowered its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 55.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The inst
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
05:44pm, Sunday, 12'th Apr 2020
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
02:05pm, Sunday, 12'th Apr 2020
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19...
Biomarin to File Regulatory Applications for Vosoritide in Q3
03:04pm, Tuesday, 07'th Apr 2020
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
Biomarin to File Regulatory Applications for Vosoritide in Q3
03:04pm, Tuesday, 07'th Apr 2020
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
Bank of New York Mellon Corp Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)
09:08am, Tuesday, 07'th Apr 2020
Bank of New York Mellon Corp acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 134,117 shares of the biotechnology
Homology Medicines (FIXX) Gets a Buy Rating from Canaccord Genuity
10:04am, Monday, 06'th Apr 2020
In a report released today, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $37.00.
